Evaluating Development Of Resistance to Osimertinib with [18F]FLT PET
Research type
Research Study
Full title
Evaluating development of resistance to Osimertinib in lung cancer with [18F] FLT-PET
IRAS ID
324364
Contact name
Gillian Price
Contact email
Sponsor organisation
University of Aberdeen
Duration of Study in the UK
1 years, 5 months, 29 days
Research summary
The imaging study will examine whether we can improve the care of patients with lung cancer that are being managed using a drug called Osimertinib. The study will use a new type of PET/CT scan called [18F]FLT-PET. The [18F]FLT is the radioactive tracer that produces information about how quickly the tumour is growing.
Osimertinib inhibits growth of lung cancer by inhibiting a protein called Epidermal Growth Factor Receptor (EGFR). Researchers want to develop an effective method to know when lung cancer tumours are developing resistance to Osimertinib treatment ie when the tumours become less responsive to this drug. One way of doing this is to study how quickly that tumour cells are growing. PET scans using the radiotracer called [18F]FLT is a non-invasive method of obtaining this information.
The intention is to assess how proliferation of Osimertinib-treated lung tumours changes over an extended time period (e.g. 2 or 3 years) to determine if there is an increase in proliferation rate. By comparing the results of [18F]FLT-PET scans over time with the status of the patient's EGFR protein the researchers hope to determine if [18F]FLT-PET scans can give an indication of the development of resistance to Osimertinib treatment
8 patients will undergo two [18F]FLT PET scans during their treatment with Osimertinib, the first between 6-12 months after starting the drug, and the second approximately 6 months later. A third scan may be performed at a further 6 month interval in patients suspected to be progressing. Corresponding blood tests will also be taken at the same time points.
REC name
North of Scotland Research Ethics Committee 1
REC reference
24/NS/0124
Date of REC Opinion
4 Nov 2024
REC opinion
Favourable Opinion